JP2007509146A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509146A5 JP2007509146A5 JP2006536678A JP2006536678A JP2007509146A5 JP 2007509146 A5 JP2007509146 A5 JP 2007509146A5 JP 2006536678 A JP2006536678 A JP 2006536678A JP 2006536678 A JP2006536678 A JP 2006536678A JP 2007509146 A5 JP2007509146 A5 JP 2007509146A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- amount
- inhibitor
- pharmaceutical composition
- levodopa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 17
- 229960003638 dopamine Drugs 0.000 claims 13
- 239000003112 inhibitor Substances 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229940125532 enzyme inhibitor Drugs 0.000 claims 8
- 239000002532 enzyme inhibitor Substances 0.000 claims 8
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 7
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 7
- 229960004502 levodopa Drugs 0.000 claims 7
- 230000002503 metabolic effect Effects 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000002243 precursor Substances 0.000 claims 7
- 238000013268 sustained release Methods 0.000 claims 6
- 239000012730 sustained-release form Substances 0.000 claims 6
- 208000018737 Parkinson disease Diseases 0.000 claims 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 3
- 102000004031 Carboxy-Lyases Human genes 0.000 claims 2
- 108090000489 Carboxy-Lyases Proteins 0.000 claims 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical group C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 229960004205 carbidopa Drugs 0.000 claims 2
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical group NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 2
- 229960001344 methylphenidate Drugs 0.000 claims 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51297303P | 2003-10-20 | 2003-10-20 | |
| PCT/US2004/034121 WO2005042101A1 (en) | 2003-10-20 | 2004-10-14 | Composition and dosage form for sustained effect of levodopa |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509146A JP2007509146A (ja) | 2007-04-12 |
| JP2007509146A5 true JP2007509146A5 (OSRAM) | 2009-05-07 |
Family
ID=34549241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006536678A Pending JP2007509146A (ja) | 2003-10-20 | 2004-10-14 | レボドーパの持続効果のための組成物及び投与形 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050113452A1 (OSRAM) |
| EP (1) | EP1675651A1 (OSRAM) |
| JP (1) | JP2007509146A (OSRAM) |
| KR (2) | KR100894465B1 (OSRAM) |
| AU (1) | AU2004285436C1 (OSRAM) |
| CA (1) | CA2553156A1 (OSRAM) |
| EA (1) | EA200600626A1 (OSRAM) |
| IL (1) | IL174591A0 (OSRAM) |
| MX (1) | MXPA06004327A (OSRAM) |
| NZ (1) | NZ546662A (OSRAM) |
| WO (1) | WO2005042101A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7674480B2 (en) | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| DE10214188B4 (de) | 2002-03-28 | 2005-08-25 | Siemens Ag | Verfahren zur gesicherten Übertragung von Daten, insbesondere zur Übertragung über eine Luftschnittstelle |
| MX2007001058A (es) * | 2004-07-26 | 2007-04-16 | Teva Pharma | Formas de dosificacion con tableta nucleo recubierta entericamente. |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| CA2580329C (en) | 2004-09-13 | 2015-01-06 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery |
| WO2007011701A1 (en) * | 2005-07-15 | 2007-01-25 | Transform Pharmaceuticals, Inc. | Novel hydrochloride salts of levodopa |
| US20070178149A1 (en) * | 2005-11-07 | 2007-08-02 | Moshe Flashner-Barak | Levodopa compositions |
| RU2484815C2 (ru) * | 2006-05-31 | 2013-06-20 | Зольвай Фармасьютиклз Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| US8765178B2 (en) | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
| EP1977746B8 (en) * | 2007-04-02 | 2014-09-24 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
| US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
| CA2974324A1 (en) | 2015-01-28 | 2016-08-04 | Zita S. Netzel | Drug delivery methods and systems |
| WO2016145373A1 (en) | 2015-03-12 | 2016-09-15 | Chrono Therapeutics Inc. | Craving input and support system |
| EP3565617A1 (en) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| CA3119992A1 (en) | 2018-11-16 | 2020-05-22 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| IT202000019303A1 (it) * | 2020-08-05 | 2022-02-05 | Univ Degli Studi Di Brescia | Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson |
| EP4316482A1 (en) * | 2022-08-01 | 2024-02-07 | 4P-Pharma | Levodopa for preventing addiction |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0252290B1 (en) * | 1986-06-10 | 1992-06-03 | CHIESI FARMACEUTICI S.p.A. | Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof |
| ZA889189B (en) * | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| US4983400A (en) * | 1986-06-16 | 1991-01-08 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| US4716246A (en) * | 1986-08-22 | 1987-12-29 | Merck & Co., Inc. | Process for L-dopa |
| US5994392A (en) * | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US5041430A (en) * | 1989-09-18 | 1991-08-20 | Du Pont Mereck Pharmaceutical Company | Oral anticoagulant/platelet inhibitor low dose formulation |
| US5607969A (en) * | 1992-12-24 | 1997-03-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-DOPA ethyl ester to treat Parkinson's disease |
| US6117453A (en) * | 1995-04-14 | 2000-09-12 | Pharma Pass | Solid compositions containing polyethylene oxide and an active ingredient |
| US5840756A (en) * | 1995-07-21 | 1998-11-24 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition of L-DOPA ester |
| US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| US6797283B1 (en) * | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
| US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| AU2001268722B8 (en) * | 2000-06-23 | 2005-09-29 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| EA005537B1 (ru) * | 2001-07-10 | 2005-04-28 | Тева Фармасьютикал Индастриес Лтд. | Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата |
| US20040052843A1 (en) * | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
| EA006053B1 (ru) * | 2001-12-24 | 2005-08-25 | Тева Фармасьютикал Индастриес Лтд. | Твёрдая лекарственная форма, способ её изготовления и устройство |
-
2004
- 2004-10-14 KR KR1020067009822A patent/KR100894465B1/ko not_active Expired - Fee Related
- 2004-10-14 US US10/966,090 patent/US20050113452A1/en not_active Abandoned
- 2004-10-14 WO PCT/US2004/034121 patent/WO2005042101A1/en not_active Ceased
- 2004-10-14 JP JP2006536678A patent/JP2007509146A/ja active Pending
- 2004-10-14 NZ NZ546662A patent/NZ546662A/en unknown
- 2004-10-14 CA CA002553156A patent/CA2553156A1/en not_active Abandoned
- 2004-10-14 EA EA200600626A patent/EA200600626A1/ru unknown
- 2004-10-14 EP EP04795307A patent/EP1675651A1/en not_active Withdrawn
- 2004-10-14 MX MXPA06004327A patent/MXPA06004327A/es unknown
- 2004-10-14 KR KR1020087029777A patent/KR20080109101A/ko not_active Ceased
- 2004-10-14 AU AU2004285436A patent/AU2004285436C1/en not_active Ceased
-
2006
- 2006-03-27 IL IL174591A patent/IL174591A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509146A5 (OSRAM) | ||
| JP5241228B2 (ja) | 非ステロイド性抗炎症薬、鬱血除去薬および鎮静作用の少ない抗ヒスタミン薬を含む多層錠 | |
| JP5202522B2 (ja) | 制御性放出製剤および関連する方法 | |
| CA2668884C (en) | Layered pharmaceutical formulations | |
| ES2333308T3 (es) | Composiciones que contienen ambas antihistaminas sedantes y no sedantes. | |
| US10512621B2 (en) | Methods of treating posttraumatic stress disorder with acamprosate salts | |
| JP2020528075A (ja) | 過度の眠気を処置するための方法および組成物 | |
| RU2011110765A (ru) | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения | |
| JP2005507400A5 (OSRAM) | ||
| JP2005512995A5 (OSRAM) | ||
| ES3041483T3 (en) | Pulsatile drug delivery system for treating morning akinesia | |
| CA2601289A1 (en) | Once-a-day oxycodone formulations | |
| ATE350040T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| JP2010523587A5 (OSRAM) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2005528430A5 (OSRAM) | ||
| JP2010524989A (ja) | 関節炎における痛みの治療のためのタペンタドール | |
| US20040137062A1 (en) | Chronotherapy tablet and methods related thereto | |
| KR100894465B1 (ko) | 레보도파의 지속적 효과를 위한 조성물 및 제형 | |
| CN116159052A (zh) | 联合用药应用以及一种药用组合物及其应用 | |
| EP2785337B1 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| JP2018506590A (ja) | トリパルス放出型賦活薬製剤 | |
| JP2024501235A (ja) | レボドパ投薬レジメン | |
| TW201626990A (zh) | 含有褪黑激素和舍曲林的口服複合錠劑 | |
| GEP20063804B (en) | Once-a-day oxycodone formulations |